In vitro drug release pattern from cryp in methanol, cryp suspension, SLN-CRYP suspension in water/HSA. Points represent mean ± S.E.M (n = 25). Assessment of in vitro release from Cryptolepine from the lipid formulation was done using the Dialysis bag method.

Effect of cryptolepine and SLN-CRYP on PTZ-induced seizure-like behavior in Zebrafish. Adult Zebrafish were injected (i.p.) with PTZ 10 min after pretreatment with cryptolepine (2.5 and 5 mg/kg), SLN-CRYP (2.5 and 5 mg/kg), diazepam (2 mg/kg). They were transferred to a 15 L observation tank containing water up to three-quarters of its capacity. After recovery from anesthesia, the zebrafish behavior was recorded for a period of 10 min. The recording was scored for the A) Latency to seizure onset (s) B) mean maximum seizure score over 600 s for each group C) Total distance swam over 600 s D) Time spent in the lower and upper zones of the fish tank for each group (s). Data are expressed as Mean ± S.E.M, n = 10, analyzed by A) two-way ANOVA and B) one-way ANOVA, followed by Tukey test *P < 0.05, **P < 0.01 and ***P < 0.001 in comparison to the negative control (PTZ) group.

Secondary binding curve of [3H] nitrendipine binding to the human Ca channel v1.2 receptor together with different concentrations of nifedipine and cryptolepine. Points represent the Mean ± S.E.M from a triplicate experiment.

Secondary binding curve of [3H] DTG binding to the human Sigma 2 receptor together with different concentrations of haloperidol and cryptolepine. Points represent the Mean ± S.E.M. from three experiments.